Want to join the conversation?
$BIIB and Swedish Orphan Biovitrum said they will present updated data on long-term safety and efficacy of the companies' novel extended half-life therapies, ELOCTATE for hemophilia A and ALPROLIX for hemophilia B. Hemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.